Hemab Therapeutics (COAG) vs Kailera Therapeutics (KLRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Hemab Therapeutics is the larger company by market cap ($1.44 billion vs $1.30 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COAG | KLRA |
|---|---|---|
| Share price | $30.89 | $10.00 |
| Market cap | $1.44B | $1.30B |
| 1-day change | +7.63% | -5.03% |
| EPS (TTM) | $-4.33 | $-4.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.42 | $28.23 |
| 52-week low | $23.00 | $9.76 |
| Distance from 52-week high | -44.26% | -64.58% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +98.12% | +324.00% |
| Average volume | 453.97K | 861.01K |
| Shares outstanding | 46.71M | 129.64M |
| Employees | 59 | 145 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Hemab Therapeutics
COAG stock →Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees
About Kailera Therapeutics
KLRA stock →Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
COAG vs KLRA FAQ
Which is bigger, Hemab Therapeutics or Kailera Therapeutics?
Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.44B compared with $1.30B for Kailera Therapeutics (KLRA).
Are Hemab Therapeutics and Kailera Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Hemab Therapeutics and Biotechnology: Pharmaceutical Preparations for Kailera Therapeutics.